Uygun, VedatKarasu, GulsunYalcin, KorayOzturkmen, SedaDaloglu, HayriyeCelen, Safiye SunaHazar, Volkan2024-05-192024-05-1920231306-133Xhttps://doi.org10.4999/uhod.237292https://hdl.handle.net/20.500.12713/4890Busulfan (BU)-based myeloablative conditioning is a standard conditioning regimen for children with AML; however, it is not clear yet which combination of cyclophosphamide (CY) and fludarabine (FLU) is most effective. We performed a study to compare the results of BUCY120 and BU-FLU in pediatric patients with AML in CR1 undergoing allo-HSCT from matched sibling donors. With the combination of BU, 15 patients were given 120 mg/kg of CY, and 12 patients were given 150 mg/m2 of FLU, respectively, in the condition regimen. Patients treated with BUFLU relapsed less than those treated with BUCY120 (p= 0.03). Moreover, these patients engrafted platelets earlier than the BUCY120 administered patients (p= 0.03). The frequency of complications in both groups was comparable. There was no significant difference in survival analysis between the groups. BUFLU has a low toxicity profile, making it a reasonable choice for children with AML in CR1 with low risk and a lower relapse frequency compared to BUCY120.eninfo:eu-repo/semantics/closedAccessChildrenAmlConditioningFludarabineLeukemiaArticle334206211WOS:001157848500006N/A10.4999/uhod.237292